Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer
- Author:
Hyo Chun LEE
1
;
Jong Hoon LEE
;
Sea Won LEE
;
Joo Hwan LEE
;
Mina YU
;
Hong Seok JANG
;
Sung Hwan KIM
Author Information
- Publication Type:Original Article
- Keywords: Biliary tract neoplasms; Radiotherapy; Adjuvant; Survival; Toxicity
- MeSH: Arm; Biliary Tract Neoplasms; Biliary Tract; Cholangiocarcinoma; Follow-Up Studies; Humans; Multivariate Analysis; Radiotherapy; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Recurrence; Retrospective Studies; Survivors
- From:Radiation Oncology Journal 2019;37(4):279-285
- CountryRepublic of Korea
- Abstract: PURPOSE: This study was conducted to compare the outcome of three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) for the postoperative treatment of biliary tract cancer.MATERIALS AND METHODS: From February 2008 to June 2016, 57 patients of biliary tract cancer treated with curative surgery followed by postoperative 3D-CRT (n = 27) or IMRT (n = 30) were retrospectively enrolled.RESULTS: Median follow-up time was 23.6 months (range, 5.2 to 97.6 months) for all patients and 38.4 months (range, 27.0 to 89.2 months) for survivors. Two-year recurrence-free survival is higher in IMRT arm than 3D-CRT arm with a marginal significance (25.9% vs. 47.4%; p = 0.088). Locoregional recurrence-free survival (64.3% vs. 81.7%; p = 0.122) and distant metastasis-free survival (40.3% vs. 55.8%; p = 0.234) at two years did not show any statistical difference between two radiation modalities. In the multivariate analysis, extrahepatic cholangiocarcinoma, poorly-differentiated histologic grade, and higher stage were significant poor prognostic factors for survival. Severe treatment-related toxicity was not significantly different between two arms.CONCLUSIONS: IMRT showed comparable results with 3D-CRT in terms of recurrence, and survival, and radiotherapy toxicity for the postoperative treatment of biliary tract cancer.
